Jiangsu Weiqida Pharmaceutical Co., Ltd. (formerly known as Shanghai Xiandai Pharmaceutical Haimen Co., Ltd.) was established in February 2010 in Nantong City, Jiangsu Province. It is affiliated with Shanghai Xiandai Pharmaceutical Co., Ltd. (hereinafter referred to as Sinopharm Xiandai) and is a wholly-owned subsidiary of Sinopharm Group Weiqida Pharmaceutical Co., Ltd. With a registered capital of RMB 800 million, it was renamed Jiangsu Weiqida Pharmaceutical Co., Ltd. in September 2020.
The company has an Innovation Development Center, relying on the China Pharmaceutical Industry Research Institute Co., Ltd. under China National Pharmaceutical Group Co., Ltd., with strong R&D technology, professional talent teams and advanced equipment and instruments. It focuses on developing characteristic APIs with high technological content, high added value and low emissions, and is committed to providing corresponding API and intermediate supporting supplies for key major varieties, potential varieties and newly approved products of Sinopharm Xiandai (stock code: 600420). The company's main products cover anti-infection, cardiovascular, big health and other fields, and its products cover more than 20 countries and regions. The company has successively passed authoritative certifications such as NMPA, FDA, WHO, HC, and ANVISA, and can provide long-term services to renowned global pharmaceutical companies.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows